These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2112405)

  • 1. The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure.
    Elborn JS; Riley M; Stanford CF; Nicholls DP
    Br J Clin Pharmacol; 1990 May; 29(5):519-24. PubMed ID: 2112405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study.
    Hori M; Sato H; Ozaki H; Inoue M; Naka M; Fukunami M; Fukushima M; Kunisada K
    Heart Vessels; 1992; 7(3):133-40. PubMed ID: 1500398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flosequinan in chronic heart failure: how is exercise capacity improved?
    Banning AP; Ramsey MW; Jones EA; Evans W; Carolan G; Jones CH; Henderson AH
    Eur J Clin Pharmacol; 1996; 51(2):133-8. PubMed ID: 8911877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
    Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
    J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
    Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR
    BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure.
    Thomas P; O'Gorman DJ; Sheridan DJ
    Br J Clin Pharmacol; 1993 Dec; 36(6):539-46. PubMed ID: 12959270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of flosequinan on exercise capacity and symptoms in severe heart failure.
    Elborn JS; Stanford CF; Nicholls DP
    Br Heart J; 1989 Apr; 61(4):331-5. PubMed ID: 2653391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic vasodilator therapy with flosequinan in congestive heart failure.
    Haas GJ; Binkley PE; Leier CV
    Clin Cardiol; 1990 Jun; 13(6):414-20. PubMed ID: 2188766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and long-term effects of flosequinan in patients with chronic cardiac failure.
    Marchionni N; Moschi G; Di Bari M; Burgisser C; Fumagalli S; Boncinelli L; Tarantini F; Ferrucci L
    Am Heart J; 1993 Jul; 126(1):147-54. PubMed ID: 8322657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure.
    Silke B; Tennet H; Fischer-Hansen J; Keller N; Heikkila J; Salminen K
    Eur Heart J; 1992 Aug; 13(8):1092-100. PubMed ID: 1505560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.
    Packer M; Narahara KA; Elkayam U; Sullivan JM; Pearle DL; Massie BM; Creager MA
    J Am Coll Cardiol; 1993 Jul; 22(1):65-72. PubMed ID: 8509565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of flosequinan on hemodynamics and oxygen delivery in cor pulmonale.
    Elborn JS; Richardson G; Murphy P; MacMahon J
    Chest; 1992 Oct; 102(4):1155-60. PubMed ID: 1395760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A non-invasive evaluation of flosequinan on haemodynamics and exercise capacity in chronic congestive heart failure.
    Motro M; Freimark D; Feinberg MS; Wynne RD; King C; Schneeweiss A
    Int J Clin Pharmacol Res; 1993; 13(3):143-9. PubMed ID: 8225697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
    Burstein S; Semigran MJ; Dec GW; Boucher CA; Fifer MA
    J Am Coll Cardiol; 1992 Oct; 20(4):822-9. PubMed ID: 1527293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
    Kessler PD; Packer M; Medina N; Yushak M
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise tolerance in patients with heart failure--how should it be measured?
    Cowley AJ; Fullwood L; Stainer K; Hampton JR
    Eur Heart J; 1991 Jan; 12(1):50-4. PubMed ID: 2009893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the hemodynamic effects of the long-acting peripheral vasodilator flosequinan in patients with chronic heart failure].
    Abdurakhmanov US; Naumov VG; Shevliagin SA; Novikov SV; Mareev VIu; Belenkov IuN
    Kardiologiia; 1991 Nov; 31(11):49-51. PubMed ID: 1805065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure.
    Isnard R; Lechat P; Pousset F; Carayon A; Kalotka H; Chikr H; Salloum J; Thomas D; Komajda M
    Fundam Clin Pharmacol; 1997; 11(1):83-9. PubMed ID: 9182081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of flosequinan in heart failure.
    Cowley AJ
    Am Heart J; 1991 Mar; 121(3 Pt 1):983-8. PubMed ID: 2000777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
    Moe GW; Rouleau JL; Charbonneau L; Proulx G; Arnold JM; Hall C; de Champlain J; Barr A; Sirois P; Packer M
    Am Heart J; 2000 Apr; 139(4):587-95. PubMed ID: 10740139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.